Market Vectors Biotech ETF (NYSEArca: BBH)
2012: 46.9%
2013: Up 57.4%
Comment: When the final closing bell for 2013 rings, there is an excellent chance that a few of the ETFs that ranked among both this and last year’s top performers will be biotech funds. BBH has a chance as it has performed noticeably better in 2013 than it did last year and that is saying something. This is one biotech ETF for investors that prefer large-cap names like Amgen (NasdaqGM: AMGN) and Celgene (NasadqGM: CELG) because the biggest biotechs dominate BBH.